Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 34

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 34
---
us supplement and any related free writing prospectus, together
with the information incorporated herein by reference as described under the headings “Where You Can Find More Information”
and “Incorporation of Certain Information by Reference” before buying any of the securities being offered.

<div align='center'>1

SUMMARY</div>

The following summary highlights
information contained elsewhere in this prospectus or incorporated by reference herein and does not contain all the information that may
be important to purchasers of our securities. You should carefully read this prospectus, all documents incorporated by reference, any
prospectus supplement and any related free writing prospectus, and the additional information described under the caption “Where
You Can Find More Information” in this prospectus, before buying any of the securities being offered. References in this prospectus
to “Armata,” the “Company,” “we,” “us” and “our” refer to Armata Pharmaceuticals, Inc.
and its subsidiaries, on a consolidated basis, unless the context requires otherwise.

Our Company

We
are a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for
the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.
We have completed three Phase 2 clinical trials to date. We see bacteriophages as a potentially safer and effective alternative to antibiotics
and an essential response to the growing bacterial resistance to current classes of antibiotics. Bacteriophages or “phages”
have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while
uniquely preserving the normal human microbiome or “healthy bacteria”. This is in direct contrast to traditional broad-spectrum
antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as Clostridium difficile.
We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics,
especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or
“superbug” strains of bacteria. We are a leading developer of clinical-stage phage therapeutics of high purity, and believe
we are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections.

We
are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered
(synthetic) bacteriophages with our proprietary phage-specific host-engineered current Good Manufacturing